Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Torino C et al. | Vitamin D and methylarginines in chronic kidney disease (CKD). | 2017 | PLoS ONE | pmid:28976989 |
Chung S et al. | Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin. | 2017 | PLoS ONE | pmid:28753620 |
Xun J et al. | JMJD3 suppresses stem cell-like characteristics in breast cancer cells by downregulation of Oct4 independently of its demethylase activity. | 2017 | Oncotarget | pmid:28423536 |
Poveda J et al. | MXRA5 is a TGF-β1-regulated human protein with anti-inflammatory and anti-fibrotic properties. | 2017 | J. Cell. Mol. Med. | pmid:27599751 |
Zheng JQ et al. | Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients. | 2016 | Nutrients | pmid:27827962 |
Manjarres L et al. | Budget impact of secondary hyperparathyroidism treatment in chronic kidney disease in an Ecuadorian social security hospital. | 2016 | BMC Health Serv Res | pmid:27566059 |
Nieuwland AJ et al. | Activation of the vitamin D receptor selectively interferes with calcineurin-mediated inflammation: a clinical evaluation in the abdominal aortic aneurysm. | 2016 | Lab. Invest. | pmid:27239732 |
El-Shemi AG et al. | Paricalcitol Enhances the Chemopreventive Efficacy of 5-Fluorouracil on an Intermediate-Term Model of Azoxymethane-Induced Colorectal Tumors in Rats. | 2016 | Cancer Prev Res (Phila) | pmid:27020656 |
Lee AS et al. | Paricalcitol attenuates lipopolysaccharide-induced myocardial inflammation by regulating the NF-κB signaling pathway. | 2016 | Int. J. Mol. Med. | pmid:26954764 |
Egido J et al. | The pleiotropic effects of paricalcitol: Beyond bone-mineral metabolism. | 2016 | Nefrologia | pmid:26705959 |